Drug Trial Radar · NCT04356495
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
412
Actual
Start
Jul 29, 2020
Primary completion
Oct 8, 2021
Study completion Oct 22, 2021
Sponsor
- Lead sponsor
- University Hospital, BordeauxAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Bordeaux
- First posted
- Apr 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In adults with COVID-19 without criteria for hospitalization or oxygen therapy but with risk factors for aggravation, early treatment may avoid hospitalization, indication for oxygen therapy or death. No treatment is currently validated for this indication.
Conditions
- Corona Virus Infection
- Sars-CoV2
Interventions
VitaminsDietary supplement
2 tablets daily from the first day (day 0) to day 9
TelmisartanDrug
1 tablet daily from the first day (day 0) to day 9
CiclesonideDrug
2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
interferon β-1bDrug
A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pilot Phase: Proportion of participants who had a Grade 3 or 4 adverse eventTime frame: From inclusion (day0) to day 14
- Efficacy phase: DeathTime frame: From inclusion (day0) to day 14
- Efficacy phase: oxygen therapyTime frame: From inclusion (day0) to day 14
- Efficacy phase: hospitalizationTime frame: From inclusion (day0) to day 14
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Bordeaux university Hospital
Bordeaux, France
CHU de Dijon-Bourgogne
Dijon, France
CHU de Montpellier
Montpellier, France
CHRU de Nancy
Nancy, France
Groupe hospitalier Paris Saint Joseph
Paris, France
CNGE
Paris, France
CHU de Toulouse
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.